Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
34.37
-1.28 (-3.59%)
At close: May 13, 2025, 4:00 PM
34.41
+0.04 (0.12%)
Pre-market: May 14, 2025, 8:23 AM EDT
HRMY Revenue
Harmony Biosciences Holdings had revenue of $184.73M in the quarter ending March 31, 2025, with 19.48% growth. This brings the company's revenue in the last twelve months to $744.85M, up 20.62% year-over-year. In the year 2024, Harmony Biosciences Holdings had annual revenue of $714.73M with 22.80% growth.
Revenue (ttm)
$744.85M
Revenue Growth
+20.62%
P/S Ratio
2.63
Revenue / Employee
$2,779,299
Employees
268
Market Cap
1.97B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
HRMY News
- 7 days ago - Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance - Business Wire
- 15 days ago - Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025 - Business Wire
- 5 weeks ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Connect - Accesswire
- 5 weeks ago - Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome - Business Wire
- 5 weeks ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Reach Out - Accesswire
- 5 weeks ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 5 weeks ago - Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire